{"schema_version":"secwatch.filing_event.v1","accession":"0001232524-22-000045","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.889342+00:00","generated_at":"2026-06-22T00:44:05.724263+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jazz Pharma Q3 revenue $940.7M (+12% YoY); raises FY guidance mid-point to $3.65B","bullets":["Q3 total revenue $940.7M, up 12% YoY; driven by Xywav, Epidiolex, and Rylaze demand.","Raises 2022 total revenue guidance mid-point to $3.65B, up from prior range.","Operating cash flow YTD $930M; cash $899.4M; net leverage ratio 2.9x.","More narcolepsy patients now on Xywav than Xyrem as of October 2022 milestone.","Pipeline progress: first patients enrolled in Phase 1 JZP815 and Phase 3 Epidyolex in Japan."],"urls":{"canonical":"https://secwatch.observer/filing/0001232524-22-000045","json":"https://secwatch.observer/filing/0001232524-22-000045.json","markdown":"https://secwatch.observer/filing/0001232524-22-000045.md","text":"https://secwatch.observer/filing/0001232524-22-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000123252422000045/0001232524-22-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000123252422000045/jazz-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:44:05.724263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}